An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naive, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone.

Trial Profile

An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naive, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Raltegravir (Primary) ; Atazanavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jan 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 19 May 2012 Companies added in association field as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top